These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Inhibiting the renin-angiotensin system: why and in which patients. Berra K; Miller NH J Am Acad Nurse Pract; 2009 Jan; 21(1):66-75. PubMed ID: 19125897 [TBL] [Abstract][Full Text] [Related]
45. Pathophysiology of atrial fibrillation: insights into the renin-angiotensin system. Le Heuzey JY; Marijon E; Chachoua K; Waintraub X; Lepillier A; Otmani A; Lavergne T; Pornin M Arch Cardiovasc Dis; 2008; 101(11-12):787-91. PubMed ID: 19059574 [TBL] [Abstract][Full Text] [Related]
46. Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy? Weber MA; Giles TD Rev Cardiovasc Med; 2006; 7(2):45-54. PubMed ID: 16915123 [TBL] [Abstract][Full Text] [Related]
47. New directions in antihypertensive drug therapy. Kaplan HR; Cohen DM; Evans DB; Krause BR; Newton RS; Ryan MJ Prog Clin Biol Res; 1986; 219():281-309. PubMed ID: 2878440 [No Abstract] [Full Text] [Related]
48. [Beta blocking agents and arterial hypertension]. Squadrito G G Clin Med; 1979 May; 60(5):347-65. PubMed ID: 39861 [No Abstract] [Full Text] [Related]
50. [Pharmacological and immunological approaches to inhibiting the renin-angiotensin system]. Eliseev OM Biull Vsesoiuznogo Kardiol Nauchn Tsentra AMN SSSR; 1987; 10(1):105-9. PubMed ID: 3300696 [No Abstract] [Full Text] [Related]
51. Is it the the renin-angiotensin-aldosterone blockade a comprehensive tool for the management of cardiovascular risk? Borghi C; Grassi G J Hypertens; 2004 Mar; 22(3):463-5. PubMed ID: 15076149 [No Abstract] [Full Text] [Related]
52. Obesity hypertension: the rationale for renin-angiotensin system blockade. Chan NN; Tong PC; Kong AP; Chan JC Hong Kong Med J; 2005 Jun; 11(3):217-20. PubMed ID: 15951590 [No Abstract] [Full Text] [Related]
54. Role of renin-angiotensin system blockades in reciprocal relationship between insulin resistance and endothelial dysfunction. Koh KK; Sakuma I; Quon MJ Hypertension; 2010 Dec; 56(6):e169; author reply e170. PubMed ID: 21059993 [No Abstract] [Full Text] [Related]
55. CKD treatment: time to alter the focus to albuminuria? de Zeeuw D; Parekh R; Soman S Adv Chronic Kidney Dis; 2011 Jul; 18(4):222-3. PubMed ID: 21782127 [No Abstract] [Full Text] [Related]
56. Renin inhibitors in the management of hypertension. Oparil S J Clin Hypertens (Greenwich); 2007 Sep; 9(9):706-7. PubMed ID: 17786072 [No Abstract] [Full Text] [Related]
57. [Blocking of beta-adrenoceptors in arterial hypertension]. Aramendia P Medicina (B Aires); 1980; 40(4):467-77. PubMed ID: 6111016 [No Abstract] [Full Text] [Related]
58. Updates on Renin-Angiotensin System Blockers in Hypertensive Patients With COVID-19. Shibata S; Kishi T Am J Hypertens; 2021 Nov; 34(11):1145-1147. PubMed ID: 34406353 [No Abstract] [Full Text] [Related]
59. The shift in the "paradigm" of the pharmacology of hypertension. Flordellis CS; Goumenos D; Kourounis G; Tsementzis SA; Paris H; Vlachojiannis J Curr Top Med Chem; 2004; 4(4):487-98. PubMed ID: 14965315 [TBL] [Abstract][Full Text] [Related]
60. Experimental analysis of anti-hypertensive effects of beta-adrenergic blocking agents. Marmo E; Caputi AP; Rossi F; Lampa E; Vacca C; Brita G; Saini RK; Di Nola R Agressologie; 1976; 17(5):279-95. PubMed ID: 13671 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]